Drug pricing has been the subject of Congressional inquiries, government investigations, and media attention. Generic drugs have long played an important role in reducing drug prices. Has the recent wave of generic drug company consolidation adversely affected pricing? Are overlap divestitures sufficient? Are prices being fixed, as might be suggested by DOJ’s criminal investigation and related civil litigation? Steven Tenn is a panelist on this topic.
For more information on this event, click here.
CRA adds Kevin Williams, Yale School of Management Professor, as academic affiliate to Antitrust Practice
“I am pleased to welcome Kevin to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Kevin is a recognized expert in...